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Abstract
The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade,
yields increasing clinical benefit to patients with different cancer types. However, decrease of MHC class I
expression is a common mechanism transformed cells take advantage of to evade CD8+ T cell-mediated antitumor
responses, negatively impacting on the outcome of immunotherapies. Hence, there is an urgent need to develop
novel approaches to overcome this limitation.
NLRC5 has been recently described as a key transcriptional regulator controlling expression of MHC class I
molecules. In this commentary, we summarize and put into perspective a study by Rodriguez and colleagues
recently published in Oncoimmunology, addressing the role of NLRC5 in melanoma. The authors demonstrate that
NLRC5 overexpression in B16 melanoma allows to recover MHC class I expression, rising tumor immunogenicity
and counteracting immune evasion. Possible ways of manipulating NLRC5 activity in tumors will be discussed.
Highlighting the therapeutic potential of modulating NLRC5 levels, this publication also encourages evaluation of
NLRC5, and by extension MHC class I pathway, as clinical biomarker to select personalized immunotherapeutic
strategies.
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Background
Major histocompatibility complex (MHC) class I display
is a fundamental defense mechanism enabling CD8+ T
lymphocytes to identify and kill infected or transformed
cells. Loss or down-regulation of MHC class I expres-
sion, accompanied by impaired expression of one or
several components of the antigen processing machinery
(APM), is frequently observed in many solid and
hematopoietic tumors [1]. Therefore, these processes
constitute common mechanisms malignant cells take
advantage of to evade natural or immunotherapy-induced
immune responses [2]. At the molecular level defective
expression of MHC class I and APM components result
from either “soft/reversible” alterations driven by epigen-
etic and posttranscriptional mechanisms or “hard/irrevers-
ible” structural genetic alterations, such as mutations or
deletions [1, 2].
It recently became clear that the nucleotide-binding
oligomerization domain (NOD)-like receptor (NLR)
family member NLRC5 (NLR caspase recruitment
domain containing protein 5) is a key transcriptional
regulator of the MHC class I pathway [3–7]. Nlrc5
knockout mouse models demonstrated the crucial role
of this NLR to maintain high MHC class I expression
in several cell types and most prominently in lymphocytes
[4–7]. Both in human and mouse, NLRC5 has a very
focused transcriptional regulatory activity, controlling
expression of classical and selected non-classical MHC
class I genes, and few genes coding for APM proteins [3,
5]. Mechanistically, this specificity is achieved through the
formation of a unique transcriptional regulatory complex
on the promoter of the target genes [3, 5, 8, 9].
We previously reported that Nlrc5-/- lymphoid targets
are killed less efficiently than controls by cytotoxic T
cells, due to their low expression of MHC class I [4].
Moreover, low NLRC5 levels were observed in certain
lymphoid tumor-derived cell lines [4]. These results
suggested that downmodulation of NLRC5 constitutes a
mechanism of tumor immunoevasion.
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Role of NLRC5 in B16 melanoma
The dedicated activity of NLRC5 to transactivate MHC
class I and APM genes renders this NLR particularly in-
teresting to study in the context of tumor development,
immunity, and escape. A recent study by Rodriguez et
al. published in Oncoimmunology presents the first ex-
perimental proof for the importance of NLRC5 in coun-
teracting tumor immune evasion [10]. The authors
generated a B16 melanoma cell line stably expressing
NLRC5. B16 cells exhibit high mutation rate, as melan-
oma in general, and reversible downregulation of the
MHC class I-mediated antigen presentation pathway,
being therefore well suited to test the immunogenic
effects of NLRC5 [11–14]. As expected, NLRC5-
expressing cells showed strongly increased MHC class I
display and augmented transcript levels of selected
APM factors. These cells were effective in presenting
exogenous and – to some extent – endogenous tumor
antigens (TAs), as shown by the activation of Pmel-1
TCR transgenic CD8+ T cells, which are specific for the
melanoma immunogenic epitope gp10025-33. Along this
line, NLRC5-expressing B16 cells formed smaller
tumors following subcutaneous implantation and fewer
foci in the lung upon intravenous injection into C57BL/
6 hosts. Whereas tumor growth was significantly
hindered when grafted into wild type mice, this was not
observed in immunodeficient or CD8+ T cell-depleted
hosts, indicating that NLRC5-expressing tumor cells
evoked a protective antitumoral cytotoxic T cell response.
A possible drawback of this set-up, is the choice of
expressing human NLRC5 in B16 cells, as it only shares
partial identity to the murine homolog and could there-
fore introduce exogenous epitopes. However, the superior
activation of Pmel-1 T cells by NLRC5-expressing
B16 melanoma strongly supports the idea that the en-
hanced capacity to present tumor antigens is the genuine
cause for the immunogenicity of this cell line.
Interestingly, the authors also tested the use of B16
melanoma cells stably expressing NLRC5 in combination
with the co-stimulatory molecule CD80 [10]. Whereas in
vitro the additional presence of CD80 led to a better im-
mune response, this setting was less efficient in
controlling tumor growth and spreading in vivo. Pos-
sibly, the cause for this counterintuitive result lies in the
interaction of CD80 with the inhibitory receptor cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) expressed
on tumor infiltrating T cells, suggesting that co-treatment
with CTLA-4 blocking agents could specifically boost
antitumor immunity in this context.
Increasing NLRC5 expression in tumor cells can thus
enhance natural anticancer immunity and immuno-
therapeutic responses especially in the case of MHC
class I low tumors. As proof of principle, the authors
immunized mice with irradiated B16 melanoma cells
expressing NLRC5. In a prophylactic setting, this treat-
ment effectively protected mice against parental B16
cell engraftment. Taken together, these data underline
the importance of NLRC5 in rising tumor immunogen-
icity and limiting tumor immune escape.
Perspectives
One way of translating these results to human therapy
envisages engineering patient-derived tumor cells to
overexpress NLRC5 in vitro. This would facilitate identi-
fication of private tumor epitopes and expansion of
endogenous antitumor T cells (Fig. 1). Obviously, such
an approach will be feasible only if the MHC class I
pathway of the tumor is devoid of structural alterations,
in which case more complex gene transfer strategies
should be considered.
Data by Rodriguez and colleagues demonstrate the
beneficial impact of increasing the activity of NLRC5 in
tumor cells in vivo (Fig. 1) [10]. The effects of NLRC5
correlate with its expression levels, which can be
enhanced by type I and II interferon (IFN), as shown
also for melanoma cells [3, 4, 6, 7, 9, 10, 15]. Provided
that NLRC5 and its target genes are devoid of irrevers-
ible genetic defects, treatment with type I IFN should
therefore represent a way of raising the levels of NLRC5
and the immunogenicity of cancer cells. IFN has already
shown potential in tumor treatment [2, 16–18], and
would have the additional benefit of inducing NLRC5 in
professional antigen-presenting cells and of lowering the
threshold for natural killer (NK) cell activation [19, 20].
It might also be of interest to study NLRC5 levels and
activity in conditions relevant to the clinic, such as
chemotherapy or radiation, which have been shown to
induce an IFN response [16, 17].
Only recently, with the advent of the so-called
“checkpoint inhibitor” and adoptive T cell transfer ther-
apies, we fully appreciate the power of the antitumoral
cytotoxic immune response [21, 22]. However, immune
evasion mechanisms targeting antigen presentation by
transformed cells remain a major obstacle to such
approaches. The role of endogenous NLRC5 with re-
gard to tumor progression and immunotherapy efficacy
is still unexplored; Nlrc5-knockout mouse models are
valuable tools to address these points, in addition to a
thorough analysis of NLRC5 transcript levels and
somatic mutations in human tumors. Indeed, data
reporting NLRC5 alterations are starting to emerge
[23–26], showing that mutations and copy number
variations are common across various tumor types. In
how far these are passenger or driver mutations needs
to be determined and will be crucial for our under-
standing of tumor immunobiology and for meeting
clinical decisions on the use of immunotherapies. We
therefore need to gain a comprehensive view of the
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mechanisms controlling antigen presentation and the
ways to influence them. As anticipated in the study by
Rodriguez and colleagues, NLRC5, given its central role
in regulating the MHCI pathway, shows promise to
improve immunotherapies.
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Fig. 1 Potential applications of NLRC5 in immunotherapy. NLRC5 is a specific transactivator of MHC class I and a subset of APM genes.
An increase or recovery of NLRC5 expression in tumor cells could therefore improve tumor antigen (TA) presentation and boost the CD8+
T cell-mediated antitumor response. Manipulation of NLRC5 expression could be envisaged in vitro/ex vivo and/or directly in patients. In
vitro, and anyway in the case of irreversible mutations, gene transfer strategies might be considered. Alternatively, type I IFN is known to
raise NLRC5 expression. These approaches will facilitate identification of private TAs by mass spectrometric analysis and expansion of
TA-specific T cell clones in the perspective of transfer therapies. In addition, type I IFN could be administrated to patients, possibly in
combination with chemotherapy, radiations, or checkpoint inhibitors, in order to increase tumor immunogenicity and improve the
overall therapeutic benefit
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